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Abstract
Pyridoxal 5’-phosphate (PLP), the active form of vitamin B6, functions as a cofactor in humans for
more than 140 enzymes, many of which are involved in neurotransmitter synthesis and degradation.
A deficiency of PLP can present, therefore, as seizures and other symptoms which are treatable with
PLP and/or pyridoxine. Deficiency of PLP in the brain can be caused by inborn errors affecting B6
vitamer metabolism or by inactivation of PLP; by compounds accumulating as a result of inborn
errors of other pathways or by ingested small molecules. Whole exome sequencing of 2 children
from a consanguineous family with pyridoxine-dependent epilepsy revealed a homozygous
nonsense mutation in proline synthetase co-transcribed homolog (bacterial) (PROSC), a PLP-
binding protein of hitherto unknown function. Subsequent sequencing of 29 unrelated indivduals with
pyridoxine-responsive epilepsy identified 4 additional children with biallelic PROSC mutations. Pre-
treatment cerebrospinal fluid samples showed low PLP concentrations and evidence of reduced
activity of PLP-dependent enzymes. However, cultured fibroblasts showed excessive PLP
accumulation. An E.coli mutant, lacking the PROSC homologue (ΔYggS) is pyridoxine-sensitive;
complementation with human PROSC restored growth whilst hPROSC bearing p.Leu175Pro,
p.Arg241Gln and p.Ser78Ter did not. PLP, a highly reactive aldehyde, poses a problem for cells -
how to supply enough PLP for apoenzymes while maintaining free PLP concentrations low enough
to avoid unwanted reactions with other important cellular nucleophiles. Whilst the mechanism
involved is not fully understood our studies suggest that PROSC is involved in intracellular
homeostatic regulation of PLP, supplying this cofactor to apoenzymes while minimizing any toxic
side reactions.
Introduction
Pyridoxal 5’-phosphate (PLP) is a highly reactive aldehyde. This allows it to act as the cofactor for
over 140 enzyme-catalysed reactions, however, it also poses a problem for the cell - how to supply
enough PLP for all the newly synthesised apo-B6 enzymes while keeping the cellular level of free
PLP so low that it does not react with other nucleophiles (e.g. sulphydryl and amino compounds and
proteins that are not B6 enzymes). Excess intracellular PLP is hydrolysed by phosphatases and, in
the liver, pyridoxal is oxidized to pyridoxic acid. However, the mechanisms of regulation of PLP
homeostasis within the cell remain an important, as yet unresolved, issue.1
The pathways from dietary B6 vitamers to brain PLP, the PLP recycling pathways and the pathway
for catabolism of excess PLP are shown in Figure 1. There are several disorders that are known to
affect these pathways. In 1995, Waymire et al. showed that mice lacking tissue non-specific alkaline
phosphatase (TNSALP) have a reduced concentration of PLP in the brain which disrupts
neurotransmitter metabolism and causes seizures.2 In man, the clinical picture of hypophosphatasia
(ALPL [MIM: 171760]) caused by a lack of TNSALP is usually dominated by the bone disease but
pyridoxine-responsive seizures can occur.3 In 2004, Gachon et al showed that, in the mouse,
knockout of the 3 transcription factors that activate pyridoxal kinase leads to low brain levels of PLP,
dopamine and serotonin, and to severe epilepsy.4 In 2005, we described a cohort of infants with
neonatal epileptic encephalopathy and changes in CSF concentrations of neurotransmitter amine
precursors and metabolites indicating deficient activity of aromatic L-amino acid decarboxylase, the
PLP-dependent enzyme required for synthesis of dopamine and serotonin5. Raised levels of
threonine and glycine in the CSF suggested there may be a general defect of B6-dependent enzymes
and, while the infants’ seizures did not show much response to treatment with pyridoxine (PN), they
responded dramatically to PLP. We were able to show that this cohort of individuals had homozygous
mutations in PNPO encoding pyridox(am)ine 5’-phosphate oxidase, that substantially reduced the
catalytic efficiency of the enzyme. Deficiency of PNPO (MIM: 610090) impairs PLP synthesis and
recycling as is clear from Figure 1. More recently we have been able to show that individuals with
PNPO deficiency can be pyridoxine-dependent rather than only PLP-dependent.6 In 2006 we
showed that pyridoxine-dependent epilepsy is usually caused by accumulation of a metabolite that
reacts with PLP, Δ1-piperideine-6-carboxylate. This metabolite accumulates because of a block in
the pipecolic acid pathway of lysine catabolism (ALDH7A1 deficiency; MIM: 266100);7 a similar
mechanism occurs with the accumulation of 1-pyrroline-5-carboxylate in hyperprolinaemia type II
(HYRPRO2 [MIM: 239510])8. Finally, there is a group of disorders in which alkaline phosphatase
cannot be anchored because of a defect in the glycosylphosphatidylinositol anchor pathway (GPI-
AP deficiencies). Circulating alkaline phosphatase levels are high (hyperphosphatasia) and, in some
individuals seizures respond to treatment with pyridoxine.9
These days, faced with a child with seizures that show a response to either pyridoxine or to
PLP, it is possible to exclude hypophosphatasia and hyperphosphatasia, PNPO deficiency and
ALDH7A1 deficiency by DNA analysis, enzymology or metabolite analyses (or a combination).
When we do this, we are left with a group of children for whom the underlying cause remains obscure.
This paper describes the results of investigation of a consanguineous Syrian family in which there
have been 3 children affected by pyridoxine-dependent epilepsy. This led to the implication of a gene
of hitherto unknown function (PROSC [GenBank: NM_007198.3]). Subsequent investigation of a
cohort of 29 children / young adults with B6-dependent epilepsy revealed biallelic mutations in
PROSC in 4 additional individuals. Analysis of body fluids and fibroblasts of PROSC-deficient
individuals suggest that it is an intracellular binding protein that is involved in the homeostatic
regulation of free PLP levels.
PROSC is ubiquitously expressed in human tissues and is highly conserved throughout
evolution suggesting an important cellular function.10 The gene product is a cytoplasmic protein that
has a PLP-binding barrel domain similar to the N-terminus of bacterial alanine racemase and
eukaryotic ornithine decarboxylase11 to which PLP binds without affecting the quaternary structure12
and, whilst PROSC deficiency in bacteria affects amino acid metabolism, the protein has no definitive
enzyme activity.11 Recently YggS, the E.coli homolog, was implicated in PLP homeostasis.12 In the
absence of the PROSC homolog (ΔYggS strain), a pyridoxine containing disc produces a ring of
bacterial growth inhibition. We have used this to test the function of human PROSC; we
demonstrated that transfection with wild type hPROSC abolishes the ring of growth inhibition whilst
hPROSC bearing mutations found in the infants with B6-responsive epilepsy (p.Leu175Pro
[c.524T>C], p.Arg241Gln [c.722G>A] and p.Ser78Ter [c.233C>G]) did not.
Subjects and Methods
Subjects and Samples
All samples from affected individuals and their families were obtained following the approval of the
study by the Ethics committee at the University of Gothenburg and/or the National Research Ethics
Service (NRES) Committee, (London, Bloomsbury: REC Ref. 3/LO/0168). Written informed consent
was obtained for all subjects/families. Total genomic DNA was extracted from EDTA blood according
to the manufacturer’s instructions (Qiagen) or using an AutoGenFlex STAR automated system
according to the manufacturer’s protocol. Stored fibroblasts from Subjects 2, 4 and 5 were cultured
using standard methods. All fibroblasts were tested for mycoplasma contamination prior to any
experiments being performed.
Homozygosity Mapping and Whole Exome Sequencing
Copy-number neutral loss-of heterozygosity and whole exome sequencing analysis were undertaken
on the index family. The pedigree of this family is shown in Figure 2A. DNA from two siblings, one
affected (IV.6) and one unaffected (IV.5), and one affected cousin (IV.2) were analysed by
GeneChip® Human Mapping 250K Nsp I Array from Affymetrix and analysed using the software
CNAGv3.0. Several regions of copy-number neutral loss-of heterozygosity (cnn-LOH) were identified
and of these, only one overlapped in both affected individuals but were absent in the healthy sister.
This region was subsequently analysed by whole exome sequence analysis. DNA was enriched
using the Agilent SureSelect Human All Exon (Agilent Technologies) and sequenced using Illumina
HiScanSQ (Illumina). Quality assessment of the NGS sequence reads was performed by generating
QC statistics with FastQC (see Web Resources). Read alignment to the reference human genome
(hg19, UCSC assembly, February 2009) was done using BWA13 with default parameters. Quality
score recalibration, indel realignment and variant calling were performed with the GATK package.14
Variants were annotated with Annovar.15 Filtering was done with regard to exonic changes in protein-
coding genes located in the LOH-region on chromosome 8p11.23-p21.2, present in homozygous
state in both affected individuals, and finally on predicted function (synonymous changes excluded).
Sanger Sequencing of PROSC
For sequence validation, subsequent mutation screening of a cohort of 29 children who had vitamin
B6-responsive seizures, and segregation analysis, the coding exons and intron/exon boundaries of
PROSC (ENST00000328195) were PCR amplified from genomic DNA (primers listed in Table S1).
Amplicons were purified using Shrimp Alkaline phosphatase and Exonuclease I prior to sequencing
bi-directionally using the Big Dye Terminator Cycle Sequencing System version 1.1 (Applied
Biosystems) on an ABI PRISM 3730 DNA Analyzer (Applied Biosystems). Population frequencies of
identified sequence changes were obtained from the Ensembl and ExAC databases (accessed
02/08/2016). ClustalW2 software (see Web Resources) was used to align sequences.
Cloning of human PROSC cDNA from fibroblasts of affected individuals and sequence
analysis of cDNA.
Total RNA was extracted from fibroblasts using an RNeasy Mini Kit (Qiagen) according to the
manufacturer's instructions. cDNA synthesis was carried out using the SuperScript III First-Strand
Synthesis System for RT-PCR (Thermo Scientific) and oligo(dT)20 primers. Amplification of PROSC
cDNA was carried out using the reaction conditions and primers detailed in Table S2. Individual
cDNA products were gel purified using the QIAquik Gel Extraction Kit (Qiagen) and cloned into TOPO
2.1 (Thermo Scientific) and TOP10 competent cells (Invitrogen) transformed. PROSC cDNA inserts
were sequenced using the conditions and primers detailed in Table S3.
qRT-PCR.
Expression analysis of PROSC was performed using fibroblast cDNA generated as described above.
Real-time PCR was carried out on a StepOne Real-Time PCR System (Thermo Scientific) using the
following TaqMan Gene Expression Assays: PROSC (Hs00200497_m1), β-actin (4333762T) and 
GAPDH (hs02758991_g1). Relative quantification of gene expression was determined using the
2−ΔΔCt method, with β-actin and GAPDH as reference genes. 
Immunoblot analysis.
Proteins in fibroblast lysates were separated electrophoretically on a NuPAGE Novex 4 -12% Bis-
Tris Protein Gel (Thermo Fisher) and transferred to a polyvinylidene difluoride (PVDF) membrane
using an iBlot Dry Blotting System according to the manufacturer’s instructions. Blots were probed
with PROSC primary antibody raised in rabbit (1:100 in 5% TBST milk; HPA023646, Sigma) and
after incubated with donkey anti-rabbit IgG-HRP (1:5000; sc-2317, Santa Cruz Biotechnology). The
membrane was developed using the Novex ECL Chemiluminescent Substrate Reagent Kit (Thermo
Fisher) and imaged using a ChemiDoc MP System (Bio-Rad) coupled to ImageLab 4.1 software.
Equivalent loading was determined using mouse β-actin primary antibody (1:40,000; A1978, Sigma) 
and goat anti-mouse IgG antibody conjugated to HRP (1:3,000; P0447, DAKO).
B6 vitamers and 4-pyridoxic acid analysis
The method used was essentially as described by Footitt et al.16 for the measurement of plasma B6
vitamers with the following minor modifications. Fibroblast pellets were lysed and 10 μl of 
supernatant added to 110 μl of master mix (containing 40 μl of dH2O, 60 μl of 0.3N trichloroacetic 
acid (TCA) and deuterated internal standards; 100 nM D2-PLP, D2-PA and D3-PM, 10 nM D2-PN,
50 nM D3-PL). In the case of CSF 50 μl of sample was added to 70 μl of master mix (containing 60 
μl of 0.3N TCA and deuterated internal standards; 100 nM D2-PLP, D2-PA and D3-PM, 10 nM D2-
PN, 50 nM D3-PL). Supernatants were analysed by LC-MS/MS (Waters Acquity Ultra Performance
LC system linked to a triple Quadrupole Xevo TQ-S instrument) on an Acquity UPLC HSS T3 column
(1.8 μm x 2.1 mm x 50 mm) fitted with a HSS T3 VanGuard guard column (Waters) using a mixture 
of mobile phase A (3.7% acetic acid with 0.01% HFBA) and B (100% methanol) at a flow rate of 0.4
ml/minute. Details of the mobile phase gradients are shown in Table S4. The quantification of the
different analytes was performed using the transitions detailed in Table S5.
Fractionation of fibroblast cell lysates
Fibroblast cell lysate supernatants were fractionated using Amicon Ultra-0.5 ml 3 kDa Centrifugal
Filters (Millipore). The B6 vitamers in the resulting fractions (>3 kDa, < 3kDa) and in the unfiltered
supernatant were analysed using the UPLC-MS/MS method described above and were corrected
for the unfiltered protein concentration.
Cloning and Generation of PROSC Mutations by Site Directed Mutagenesis.
Wild-type human PROSC cDNA in pOTB7 (Thermo Scientific; BC012334.1; clone ID 3546307) was
used as a template. Site-directed mutagenesis was carried out using the QuikChange XL Site-
Directed Mutagenesis Kit (Stratagene) in order to generate Ser78Ter. The primers used for site
directed mutagenesis are as detailed in Supplementary Table 5. Wild-type PROSC and Ser78Ter
PROSC were subsequently amplified using the following primers: SDHuyggS-fwd (5’-
GGAATTCAGGAGGTATACACCATGTGGAGAGCTGGCAGCAT-3’) and HuyggS-rev (5’-
CGCGGATCCGGTACCTTAGTGCTCCTGTGCCACC-3’), SDHuyygS-fwd and SHuyggS-rev (5’-
ATTATTGGATCCTTATTAGTCGACTTATGCTTTTTCTAGCAGTTCCTGAACGTAG-3’) and the
resulting PCR products subcloned into the EcoRV and BamHI sites of the multiple cloning site (MCS)
of pBEY279.112 to generate pBEY332.1 and pBEY330.4. Wild-type and Ser78Ter PROSC were
subsequently amplified from pBEY332.1 and pBEY330.4 using the following primers
FW_PBAD33_SacI_RBS_ProsC 5’-TTAGCGAGCTCAGGAGGAATTCACCATGTGGAGAGCTGG
CA-3’ and RV_PBAD33_SalI_ProsC 5’-TTATTAGTCGACTTAGTGCTCCTGTGCCACCTCCAGCG
GG-3’, FW_PBAD33_SacI_RBS_ProsC and RV_PBAD33_saII_PROSC_stop 5’-TTATTAGTC
GACTTATGCTTTTTCTAGCAGTTCCTGAACGTAG-3’ to enable sub-cloning of the gene into the
SacI and SalI sites of the multiple cloning site of pBAD33 to generate the plasmid pLSP01 and
pLSP02. The Q5 site-directed mutagenesis kit, (New England Biolabs) was used essentially as
described by the manufacturer, to generate the missense mutations Arg241Gln, Leu175Pro and
Pro87Leu using the plasmid pLSP01 as template and to give pLSP07, pLSP03 and pLSP05,
respectively. The primers used for site directed mutagenesis are as detailed in Table S6.
E.coli complementation studies.
The E.coli ΔyggS (VDC6594) were freshly transformed with the empty vector (pBAD33) as negative 
control and pLSP01, pLSP02, pLSP03, pLSP05, pLSP07 as described previously.12 2 sterile discs
were set on the top of the agar and 20 μl of PN (0.1 mg/ml or 1 mg/ml) was added to the disc and 
plates were incubated overnight at 37 °C.12 The sensitivity to pyridoxine is defined as the distance
(in cm) from the disc where the ΔyggS strain does not grow. 
Results
Homozygosity Mapping and Exome Sequencing of Index Family
In order to identify shared regions of homozygosity and potential candidate genes DNA of the index
family from affected individuals IV.2 and IV.6 and the unaffected sister of IV.6 i.e. IV.5 were analysed
on a Human mapping array. Several overlapping copy-number neutral loss-of-heterozygosity
regions were identified in the affected individuals, however only one was absent in the healthy sister.
However, none of the 77 protein-coding genes in this region (chromosome 8p11.23-p21.2; Table
S7) obviously explained the seizures. Characterisation of this region using WES for IV.2 and IV.6
identified 18 exonic single nucleotide variants (SNVs) (Table S7) present in both affected individuals
after filtering. One had a stop-gain predicted function; c.233C>G (p.Ser78Ter) in PROSC (proline
synthetase co-transcribed homolog (bacterial) GenBank: NM_007198.3), a gene of unknown
function. This variant had not been reported in the dbSNP, 1000 Genomes or ExAC databases.
Sanger Sequencing of PROSC
Sequencing of PROSC in the index family (Subjects 1 - 3; Table 1) showed that this variant
segregated within the family (Figure 2A). Genotyping of 237 Swedish and 89 Syrian controls (living
in Sweden) for c.233C>G identified one heterozygote and no homozygotes. Subsequent sequencing
of PROSC in a cohort of 29 children with B6-repsonsive epilepsy (for whom ALDH7A1 and PNPO
deficiency had been excluded using genetic and/or biochemical evidence) identified potential
pathogenic variants in four additional subjects (Subjects 4 – 7) (Table 1, Figure 2B and Figures S1
and S2) and analysis of parental DNA for these families confirmed that the parents were
heterozygous carriers. Whilst the nonsense mutation p.Gln71Ter (c.211C>T), and the splice site
mutation c.320-2A>G have not been reported in the ExAc, dbSNP or Ensembl databases the
missense mutations p.Pro87Leu (c.260C>T), p.Leu175Pro (c.524T>C) and p.Arg241Gln
(c.722G>A), and the splice site mutation c.260C>T have but only in heterozygous form with a
prevalence of <0.01%.
Clinical Histories
The index family is of Syrian descent and includes three affected members with vitamin B6-
dependent seizures in whom PNPO and ALDH7A1 deficiencies were excluded; 2 siblings (IV.1 and
IV.2) and a cousin (IV.6). The pedigree in Figure 2A demonstrates an autosomal-recessive pattern
of inheritance. Clinical characteristics of the affected children are summarized in Table 2. Detailed
clinical histories of all 7 affected individuals are in the Supplemental Information and are tabulated
in Table 2.
Comparison of the Clinical Phenotypes
Of the 7 individuals with PROSC mutations, 3 had abnormal intrauterine movements (including the
one subject whose mother was being treated with pyridoxine throughout pregnancy), 4 showed signs
of fetal distress and 4 had a birth head circumference on or below the 9th centile. All affected infants
presented with seizures on day 1 of life, apart from Subject 7 who presented at 1 month. The
commonest EEG finding was burst suppression (4/7). All responded to pyridoxine treatment with an
immediate reduction in seizure frequency and severity; 2 showed respiratory depression. In the case
of subject 1, concerns about respiratory depression led to the pyridoxine being discontinued for
several weeks and this infant died. Some affected infants showed signs of systemic disease in
addition to the seizures in the first few days of life: 4/7 infants had metabolic acidosis with raised
blood lactate, 2/7 anemia and 3/7 gastrointestinal dysfunction - abdominal distension, vomiting,
necrotizing enterocolitis. On follow up, four patients had their B6 treatment changed from pyridoxine
to PLP and all showed an improvement in seizure control. The majority (5/6) of the surviving subjects
require treatment with anticonvulsants (clobazam, carbamazepine, levetiracetam and
phenobarbitone) in addition to vitamin B6 with 3/5 receiving levetiracetam for optimal seizure control.
Neonatal MRI scans where available (4/7) and with the exception of the one individual treated in
utero, showed global underdevelopment of the brain and periventricular germinolytic cysts (Figure
3, Table 3). Follow-up scans showed persistent white matter abnormalities and head circumference
measurements revealed acquired microcephaly. Whilst all subjects showed some degree of
developmental delay (Table 2) one attended normal school and leads a normal life. Minor
dysmorphic features were evident for four of the affected individuals.
Analysis of Impact of PROSC Sequence Variants found in Subjects with B6-Dependent
Epilepsy
Sequence alignment (Figure S2) of PROSC and COG0325 family members to which PROSC
belongs, shows two of the missense changes identified, p.Leu175Pro and p.Arg241Gln, affect
residues conserved across mammalian species and in bacteria and yeast. Pro87, however, is only
conserved across higher organisms. Analysis of mRNA in fibroblasts indicated that p.Leu175Pro
[c.524T>C; Subject 4] decreases PROSC expression (p<0.0001) (Figure 4A, Figure S3) resulting in
no detectable PROSC protein in fibroblasts (Figure 4B). PROSC protein is also not detectable in
fibroblasts of Subject 2 (Figure 4B), with p.Ser78Ter presumably resulting in nonsense-mediated
mRNA decay (Figure 4A). Fibroblasts were not available to study p.Gln71Ter and
p.Pro87Leu/p.Arg241Gln further.
Analysis of cDNA from Subject 5 revealed that c.207+1G>A and c.320-2A>G affect DNA
splicing (Figure 4C) and result in decreased mRNA expression (Figure 4A). The largest cDNA
product originates from c.207+1G>A and is due to inclusion of intron 2 (Figure S4) and results in
nonsense-mediated decay due to the introduction of a premature stop codon (p.Val70IlefsTer6;
Figure S4) whilst the smallest cDNA product arises due to skipping of exon 2 and an in-frame deletion
of 36 amino acids (p.Asp34_Tyr69del) and corresponds to a protein of ≈26 kDa (Figure 4B). 
Sequencing of the intermediate product revealed c.320-2A>G does not cause skipping of exon 5,
but results in deletion of the first ten amino acids of this exon and use of a cryptic splice site
(p.Ala107_Thr116del).
Biochemical Profiles of Individuals with PROSC Mutations
The response of individuals with PROSC mutations to B6 treatment indicated CNS PLP deficiency
and biochemical analyses (where available) supported this. Subjects 4 and 5 had low CSF PLP
concentrations prior to / just after starting B6 supplementation (Table 4) and Subjects 2, 4 and 5
displayed features of deficiency of aromatic L-amino acid decarboxylase (AADC),19 a B6-dependent
enzyme, including elevated CSF concentrations of 3-ortho-methyldopa, L-dopa and/or 5-
hydroxytryptophan (Table 5) and urinary organic acid analysis showed raised vanillactate. Glycine,
the substrate for the B6-dependent glycine cleavage enzyme, was on occasions slightly elevated
when Subjects 4 and 5 were off B6 supplementation (Table S8) as was alanine; a substrate of B6-
dependent alanine transaminase (Table S8). Whilst on B6 supplementation CSF amino acid levels
normalized with the exception of tyrosine (substrate of the PLP-dependent enzyme tyrosine
aminotransferase) which was slightly raised on several occasions in Subject 2 (Table S9).
Pre-treatment CSF profiling of Subject 5 revealed that homocarnosine, a histidine dipeptide
carbonyl scavenger,20 was undetectable (Table S10).
Vitamin B6 profiles of plasma and fibroblast samples from PROSC-deficient individuals
Analysis of B6 vitamer profiles of plasma samples from subjects on B6-supplementation revealed that
PROSC-deficient individuals had high plasma PLP levels but, unlike individuals with PNPO
deficiency,16 do not accumulate pyridoxine, pyridoxamine, pyridoxine phosphate and pyridoxamine
phosphate (Table S11), suggesting PNPO activity is not impaired. Plasma PLP levels, although not
as high as those seen in hypophosphatasia caused by mutations in ALPL,21 were 4–7 times higher
than reported for individuals with PNPO and PDE deficiencies receiving comparable
supraphysiological doses of B6 (Table S11, including unpublished diagnostic data, National
Hospital). TNSALP activity was normal (Table S12) in all PROSC-deficient individuals for whom it
was measured and no pathogenic sequence variants in ALPL were detected in WES data available
for Subjects 1 and 2.
Similarly to plasma, PLP levels were also found to be elevated in fibroblasts from PROSC-
deficient individuals [when grown in standard media (containing pyridoxine)], being 2–3 times those
of controls (Figure 4D). The concentration of pyridoxal was significantly elevated in cells from Subject
2 (Figure S5) and this may have arisen from phosphatase activity on elevated PLP levels.
Comparison of other B6 vitamers in affected and control fibroblasts was unremarkable.
PLP is a highly reactive aldehyde22 and can bind not only via Schiff base linkages to the
epsilon amino groups on lysine residues at the active site of B6-dependent enzymes, but can also
react with other residues of proteins23, with metabolites such as Δ1-piperideine 6-carboxylate,7,8 with
many amino acids, particularly cysteine (forming thiazolidine adducts)24,25 and with histidine
dipeptides20. Therefore, the PLP distribution between low (<3K) and high (>3K) molecular weight
fractions from control and PROSC-deficient fibroblasts was investigated. This was similar between
fractions (Figure S6) suggesting that supra-physiological cellular concentrations of PLP react non-
specifically with both proteins and small molecules.
Complementation of the Pyridoxine-Sensitive Phenotype of ΔyggS E.coli
To further explore the role of PROSC in PLP homeostasis we looked for complementation of the
pyridoxine sensitive phenotype of the ΔyggS E.coli12 by wild-type and mutant human PROSC
[Ser78Ter, Pro78Leu, Leu175Pro and Arg241Gln] (Figure 5, Table S13). Wild-type human PROSC
and Pro87Leu, which is not conserved between human PROSC and E.coli YggS, restored growth.
The missense mutations Leu175Pro and Arg241Gln, however, which affect highly conserved amino
acids across the YggS/PROSC/YBL036C family (COG0325), did not complement the ΔyggS
pyridoxine toxicity phenotype nor did the nonsense variant Ser78Ter. Interestingly Arg241Gln
appeared to exacerbate the toxicity effect of pyridoxine on the ΔyggS E.coli mutant.
Discussion
Homozygosity mapping and exome sequencing of a consanguineous family led to the discovery of
a homozygous nonsense mutation, p.Ser78Ter in PROSC, a gene of hitherto unknown function,
which segregates with a phenotype of prenatal / neonatal onset seizures that respond to treatment
with pyridoxine and PLP. The phenotype is expressed in all 3 affected children and not in 9
heterozygotes and 2 homozygous wildtype individuals in 3 generations. In a cohort of individuals
with B6-responsive epilepsy, in which known causes of B6-dependent epilepsy had been excluded,
homozygous or compound heterozygous mutations were found in PROSC in 4 of the 29 children /
young adults (14%). Little is known about the COG0325 family of proteins to which PROSC belongs.
Whilst structural studies of the yeast and E.coli family proteins26 have shown that these proteins are
similar to the N-terminal of alanine racemase and ornithine decarboxylase and bind PLP in a similar
manner they are monomeric and have no racemase activity towards any of the 20 protein amino
acids or their D-enantiomers.11,12 Indeed PLP binding does not affect the quaternary structure of the
protein.12
As with pyridoxine-dependent epilepsy due to ALDH7A1 (antiquitin) deficiency27,28 and
pyridoxine/PLP-dependent epilepsy due to PNPO deficiency,6 the clinical phenotype is dominated
by the B6-dependent seizure disorder although systemic signs such as anemia, enterocolitis,
electrolyte abnormalities and lactic acidosis may be present in the neonate. The birth head
circumference was on or below the 9th centile for 4 out of the 6 subjects with PROSC deficiency for
whom this measurement was available; birth HC is usually normal in PNPO deficiency and ALDH7A1
deficiency. Also, in PROSC deficiency we noted MRI features showing global underdevelopment of
the brain (broad gyri and narrow sulci) and later underdevelopment of white matter. Periventricular
cysts could be present in the neonatal scans. In the child treated during pregnancy, these changes
were not seen but acquired microcephaly was evident on follow-up for him and all but one of the
other PROSC-deficient individuals. All affected children had some degree of developmental delay
whereas some individuals with PNPO deficiency and 25% of individuals with ALDH7A1 deficiency
have a normal neurodevelopmental outcome.28,29
Analysis of CSF concentrations of neurotransmitter amine precursors and metabolites on
PROSC-deficient subjects off treatment showed elevation of 3-O-methyldopa (3/3) and 5-
hydroxytryptophan (2/2) – also consistent abnormalities in PNPO deficiency - but minimal or no
reduction in homovanillic acid (HVA) or 5-hydroxyindoleacetic acid (5HIAA). HVA and 5HIAA were
low in the first-described individuals with PNPO deficiency5 but not consistently in subsequently
described individuals with PNPO deficiency.30 There may be a route of production of dopamine and
hence its metabolite, HVA, that does not require AADC31 and this pathway may be active to a variable
degree in individuals with PROSC deficiency and PNPO deficiency. In the one PROSC-deficient
subject in whom CSF homocarnosine was measured, it was undetectable. This may indicate that
this carbonyl scavenger is reacting with free PLP; whether this will prove to be a specific marker for
PROSC-deficiency remains to be seen.
The plasma PLP concentration in PROSC-deficient individuals receiving pharmacological
doses of pyridoxine/PLP was higher than we see in ALDH7A1 deficiency or PNPO deficiency but
not as high as seen in hypophosphatasia21. Unlike PNPO deficiency, there was no accumulation of
pyridoxine, pyridoxamine, pyridoxine phosphate or pyridoxamine phosphate in the plasma of the
PROSC-deficient individuals. So the plasma B6 vitamer profile on treatment could be a pointer to
PROSC deficiency.
The mutations in PROSC in the children with B6-dependent epilepsy include nonsense,
missense and splice site mutations. The missense mutations, p.Leu175Pro and p.Arg241Gln affect
residues that are highly conserved from bacteria through yeast to man. However Subject 7, who had
a milder disease with onset of seizures at 1 month rather than on day 1, had a mutation on one allele
that affected a residue (Pro87) that is only conserved across higher species.
We used fibroblasts to study the effects of the PROSC mutations found in the affected
individuals on PROSC RNA and protein and B6 vitamer levels. The nonsense mutation, p.Ser78Ter,
led to a reduced PROSC mRNA level as would be expected from nonsense-mediated decay but
reduced PROSC mRNA and PROSC protein were also seen in the fibroblasts of the child
homozygous for p.Leu175Pro. The splice site mutations were confirmed to give rise to aberrant
splicing. In fibroblasts cultured in normal medium, the amounts of PLP present in the cells of the
PROSC-deficient individuals, was 2–3 times those of controls; an excess was present in both high
molecular weight and low molecular weight cell lysate fractions suggesting that the excess PLP
present was binding to proteins and small molecules indiscriminately.
An E.coli strain lacking the PROSC homologue (ΔYggS) shows growth inhibition when
exposed to a high concentration of pyridoxine and this phenotype was rescued by transfection with
wild type human PROSC but not by hPROSC bearing the p.Leu175Pro, p.Arg241Gln, and
p.Ser78Ter mutations found in affected individuals. One mutation, however, did allow hPROSC to
rescue the pyridoxine sensitivity of ΔYggS – Pro78Leu. This is unsurprising as Pro78 is not
conserved between human PROSC and E.coli YggS. Previous studies on E.coli  ΔYggS showed an
abnormality of the metabolism of amino acids and 2-oxoacids that were interpreted as indicating
deficiency of coenzyme A (CoASH) and were reversed by supplementing with pantothenate.11 It is
possible that in the absence of PROSC, free PLP rises to a level at which it reacts with and
inactivates CoASH.
Several mechanisms have been proposed to explain how the cell ensures that PLP is guided
to apo-B6 enzymes and does not react inappropriately with small molecules and proteins.32-37 It has
been suggested that PNPO and pyridoxal kinase, which are regulated by PLP feedback inhibition,32
channel PLP to certain apo-B6-enzymes.36,37 Our data suggests PROSC is involved in cellular PLP
homeostasis in man. Whilst exact mechanisms remain uncertain, we postulate that PROSC is a
PLP-carrier which, prevents PLP from reacting with other reactive molecules, supplies it to apo-
enzymes and protects it from intracellular phosphatases (Figure S7). In human PROSC deficiency
there is clear evidence of low levels of CSF PLP which are accompanied by deficient activity of PLP-
holoenzymes (e.g. AADC) and of B6-dependent epilepsy. There is also evidence of carbonyl
scavenger depletion in vivo and evidence, in cultured cells, of uncontrolled build-up of PLP with
excessive binding to proteins and small molecules.
Treatment of PROSC-deficient individuals with PLP produced better seizure control than
treatment with pyridoxine. The plasma B6 vitamer profile of a subject on pyridoxine showed very high
levels of pyridoxal and pyridoxic acid (Table S11). This suggests that the PLP produced in the liver
from the pyridoxine supplement by the sequential actions of pyridoxal kinase and PNPO, is, in the
absence of PROSC, vulnerable to degradation by intracellular phosphatases and aldehyde oxidase.
All but one of the individuals with PROSC deficiency required treatment with antiepileptic drug(s) as
well as B6. This suggests that the pathophysiology of the seizure disorder involves more than CNS
PLP deficiency; it is possible that the inappropriate reaction of PLP with proteins and small molecules
contribute to the pathogenesis of the seizures. It is also possible that variants in other genes will be
found to affect the phenotype of PROSC deficiency.
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Figure Titles and Legends
Figure 1. Enzymes and Transporters Involved in Mammalian CNS PLP Synthesis and
Homeostasis and Known Human Genetic Vitamin B6-Dependent Epilepsies
Pyridoxal 5’-phosphate (PLP); pyridoxamine 5’-phosphate (PMP); pyridoxal (PL); pyridoxine (PN);
pyridoxine 5’-phosphate (PNP); pyridoxine-5’-β-D-glucoside (PNG); intestinal phosphatases (IP); 
transporter (identity unknown;T1); pyridoxal kinase (PK); pyridox(am)ine 5’-phosphate oxidase
(PNPO); tissue non-specific alkaline phosphatase (TNSALP); pyridoxal-phosphatase (PLPase).
AOX/DH (Aldehyde oxidase [Mo cofactor] / β-NAD dehydrogenase) (1) PNPO is controlled by 
feedback inhibition from PLP. (2) PLP functions as a co-factor, forming Schiff bases with the ε-amino 
group of lysine residues of proteins. (3) PLP can be formed by recycling the cofactor from degraded
enzymes (‘salvage pathway’). (4) PLP levels, in part, are maintained by circadian clock controlled
transcription factors with PAR bZip transcription factors (DBP, HLF, TEF) targeting PK. (5) PNPO
mutations cause a B6-dependent epilepsy disorder. (6) Disorders resulting in accumulation of L-Δ1-
pyrroline-5-carboxylic acid (P5C) and Δ1-piperideine-6-carboxylic acid (P6C), (hyperprolinaemia
type II and pyridoxine-dependent epilepsy due to mutations in ALDH4A1 and ALDH7A1,
respectively) cause decreases in bioavailable PLP as do reactions with exogenous small molecules.
Figure 2. Pedigree of Index Family and Position of PROSC Variants
(A) Pedigree of index family (Subjects 1 – 3) and segregation analysis of c.233C>G; p.Ser78Ter for
this family. Affected individuals are homozygous for GG. Analysis of extended family DNA
demonstrated that both parents are heterozygous carriers of the identified variant and all other
individuals were found to either be wildtype (CC) or heterozygous (GC) for this variant. Squares
represent males, circles females, and a double line a consanguineous union. Black shapes
represent affected individuals, shown subsequently to be homozygous for c.233C>G. The diagonal
line through the square indicates that this individual has deceased. Genotypes: II.2, II.4 = GC; III.1,
III.2, III.3, III.4, III.5, = GC; III.6 = CC; IV.1, IV.2, IV.6 = GG; IV.3, IV.4 = GC; IV.5 = CC.
(B) Predicted Features of PROSC and Position of Mutations. This gene spans 17.17 kb and consists
of 8 exons. The translated protein is 275 amino acids in length. Blue arrows indicate positions of
mutations detected. The green line represents the PLP-binding barrel domain [amino acids 21–250]
and the blue line the alanine racemase N-terminal domain [amino acids 17-251]. K47 is proposed to
have an N6-pyridoxal-phosphate modification (by similarity). A cAMP & cGMP-dependent protein
kinase phosphorylation site; RKGS [amino acids 132-135] and a putative N-linked glycosylation site;
NTGS [amino acids 146-149] are also predicted. aa = amino acids.
Figure 3. CT and MRI Brain Features of Individuals with Mutations in PROSC
(A) CT head (axial) of Subject 1 at 2 months of age showing underdevelopment of brain with broad
gyri and shallow sulci as well as a cyst adjacent to the left frontal horn (white arrow). (B) & (C) MRI
scan (axial T2 weighted) of Subject 4 at 2 months of age showing underdevelopment of brain with
broad gyri and shallow sulci, as well as subcortical and deep white matter oedema and white matter
petechial haemorrhages (black arrow). (D) MRI scan (axial, T2 flair) from Subject 5 at 16 days of
age showing global underdevelopment of brain with coarse gyral pattern and bilateral large cysts
adjacent to the frontal horns. (E) MRI scan (axial, T2 flair) from Subject 5 at 1y 6mo showing global
underdevelopment of the brain with a coarse gyral pattern, more severe at the frontal poles, and
underdevelopment of white matter.
Figure 4. Loss of PROSC Expression Affects Intracellular PLP Homeostasis
(A) qRT-PCR showing PROSC expression in affected individuals and wild-type. Reference genes;
β-Actin and GAPDH. Data presented as means ± s d. Statistical analysis performed using Student’s
b c
two tailed t test; *** p<0.001. Controls; n=8 and for samples from affected individuals and
heterozygotes n=3.
(B) Western blot analysis of control fibroblasts, fibroblasts from PROSC-deficient individuals and a
Ser78Ter PROSC heterozygote. β-Actin used as control. Full-length wild-type PROSC is 30 kDa, 
faint band (Subject 5) is 26 kDa.
(C) PROSC cDNA products from wild-type and Subject 5 fibroblasts.
(D) Total fibroblast PLP of controls, PROSC-deficient individuals and Ser78Ter heterozygote. PLP
quantified relative to D2-PLP internal standard and normalized (mg cell protein). Data presented as
means ± sd. Statistical analysis performed using Student’s two tailed t test; comparison of controls
with PROSC-deficient samples p<0.0001***. QC; quality control sample. QC n=5; Controls n = 18;
PROSC-deficient subjects & Heterozygote n>3.
Figure 5. Complementation of E. coli ΔyggS with Human Wild-Type and Mutant PROSC
E.coli ΔyggS were transformed with empty vector (pBAD33) as negative control, human wild-type
PROSC, Ser78Ter, Leu175Pro, Pro87Leu or Arg241Gln and grown in the presence of discs
impregnated with a) 20 μl 0.1 mg/ml or b) 20 μl 1 mg/ml pyridoxine. Pyridoxine produces a ring or 
rings of growth inhibition around the disc. This is prevented by transfection with wild-type PROSC or
PROSC bearing the Pro87Leu mutation. It is not prevented by transfection with PROSC bearing
Ser78Ter, Leu175Pro or Arg241Gln. The latter exacerbates growth inhibition producing a filled circle
rather than a ring.
Table 1. Genotypes of Subjects with PROSC Mutations
Subject Position Nucleotide Predicted Effect Allele Frequencyb
1a Exon 3 c.233C>G (M) + c.233C>G (P) p.Ser78Ter Novel
2a Exon 3 c.233C>G (M) + c.233C>G P) p.Ser78Ter Novel
3a Exon 3 c.233C>G (M) + c.233C>G (P) p.Ser78Ter Novel
4 Exon 6 c.524T>C (M) + c.524T>C (P) p.Leu175Pro 1 in 121412
5 Intron 2
Intron 4
c.207+1G>A (M)
c.320-2A>G (P)
Splicing effect
Splicing effect
4 in 121408
Novel
6 Exon 3 c.211C>T + c.211C>T p.Gln71Ter Novel
7 Exon 4
Exon 8
c.260C>T (M)
c.722G>A (P)
p.Pro87Leu
p.Arg241Gln
2 in 121410
5 in 121407
(M) = maternal allele; (P) = paternal allele; aRelated; bData from ExAC; whilst individuals heterozygous for
p.Pro87Leu, p.Leu175Pro, p.Arg241Gln and c.207+1G>A have been reported on the ExAC database the
frequency of these variants is <0.01% and there are no reports of any homozygous individuals.
Table 2. Clinical Characteristics of Individuals with Mutations in PROSC
Subject 1 Subject2
a
Subject 3 Subject 4 Subject 5 Subject 6 Subject 7
Gender M M F F F M M
Current Age Died 4.5 m 9 y 6 y 3 y 6 m 5 y 6 m 3 y 2 m 16 y
Ethnicity (Domicile) Syrian
(Sweden)
Syrian
(Sweden)
Syrian
(Sweden)
Indian
(UK)
German
(Germany)
Indian
(UK)
Italian
(Italy)
Consanguinity + + + + - + -
Birth Gestational Age (wks) 32 40 36+6 36+3 35+1 39 39
Abnormal Intrauterine
Movements
- + + + - - -
Fetal Distress + - - + + + -
Apgar Scores 5, 10, 10 8, 9, 10 8, 8, 9 7, 8, 8 8, 8, 9 9, 9, 9 9, 9, 10
Birth head circ. centile 25-50% 2-9% 9% 90% 9% 9% 25-50%
Anemia at birth + - - + - - -
Acidosis + - + + + + -
Raised Blood Lactate + - - + + + Not known
Respiratory Distress - - - + + + -
Hypertonia (Neonatal) - + - + - + -
Hypotonia (Neonatal) - - - - + - -
Abdominal
distension/vomiting/feed
intolerance
+
NEC
- - + + - -
Irritability Not known Not known Not known + + + -
Seizure onset within 24h + + + + + + -b
Response to AEDs - Given with PN;
some
improvement
Given with
PLP/PN; some
improvement
Minimal Partial Given with
PLP; better
control
Partiald
EEG: Burst suppression + - + + + + -
Reduced background
Activity
+ + + -
Focal discharge(s) + -
Multifocal spikes + -
Seizure typee: Tonic + + + +
Clonic - - - - - + -
GTC - + + + - + +
Myoclonic + + - - + - -
Lip-smacking/
grimacing
+ - - + +
Response to pyridoxine + + + + + + +
Respiratory depression
upon treatment
with PN in neonatal period
+ - - - + - n/a
PN withdrawal undertaken
(and led to recurrence of
seizures)
+
(+)
- - - +
(+)
- -
Switch from PN to PLP
(improved seizure control)
- - +
(+)
+
(+)
+
(+)
+
(+)
-
PLP withdrawal
(recurrence of seizures)
n/a n/a - - +
(+)
+
(+)
n/a
Speech delay n/a + + + + + -
Motor delay n/a + + + + - -
Learning difficulties n/a + + + + + +
Breakthrough seizures with
fever
n/a + + - + + +
Acquired microcephaly + + + + + + -
Minor dysmorphic featuresc + + + Not known + - -
n/a = not applicable; m = months; y = years; AEDs antiepileptic drugs; GTC = generalised tonic-clonic; NEC = necrotising enterocolitis; circ. = circumference
asubject treated prophylactically; mother given 100mg pyridoxine daily through pregnancy; bsubject presented at 1 month of age; c2/4 thin upper lip, 1/4
long philtrum, 1/4 upslanting palpebral fissures, 1/4 convergent squint, 1/4 periorbital fullness; dAnticonvulsant treatment stopped at age of 8 years; erefers
to time of presentation.
Table 3. MRI Brain Features of Individuals with Mutations in PROSC
MRI Feature
Subject (age) Global
underdevelopment
of brain with
broad gyri and
shallow sulci
Microcephaly with
global
underdevelopment
of white matter
Cyst(s) White matter
oedema
Deep white
matter petechial
haemorrhagesa
Normal
1 (2 m) + +b 1 [Close to L
frontal horn]
- -
2 (3½ m)
2 (23 m)
-
-
-
-
-
-
-
-
+c
+c; c
3 (10 d)
3 (2 y 2 m)
+
+
1 [Close to L
frontal horn]d
-
-
-
-
4 (10 d)
4 (2 m)
4 (2 y)
+
+
+
-
-
-
+
-
-
-
-
-
5 (16 d)
5 (7 m)
5 (1y 6 m &
3y 11 m)
+e
+f
+g
+b
+
2 [Bilateral,
adjacent to
frontal horns])d
Have coalesced
with ventricular
system
Coalesced
-
-
-
-
-
-
6 - - - - +h
7 - - - - +h
a Asymmetrical; bToo young to determine white matter development: cTreated in utero and from birth dWith
associated haemorrhage; eWith failure of operculisation; f Magnetic resonance spectroscopy showed a low
N-acetyl asparate (NAA) / creatine ratio, a high choline/creatinine ratio and high lactate peaks in parietal
white matter; gMore severe in frontal regions; hNot reviewed in London; m = months; d = days; y = years;
L = left.
Table 4. CSF B6 Vitamer Profiles of PROSC-Deficient Individuals
Age B6 [dose] PLP PL PA PN PNP PMP PM
Ref range 1y – 18 y1 None 11 - 34 16 - 56 0.09 - 3 < 0.032 nm < 5.42 0.3 - 0.9
Subject 4 6 d3 PN [100 mg/day] <44 nm nm nm nm nm nm
Subject 5 17 m None5 6, 5 15, 15 nd 0.05, 0.08 0.9, 0.8 nd 0.1, 0.2
Subject 6 20 m PN [40 mg/kg/day] 43 nm nm nm nm nm nm
Data was not available for Subjects 1-3 and 7. nd, not detected; nm, not measured; y, years; d, day; m, months; Ref, reference; PL, pyridoxal;
PN, pyridoxine; PM, pyridoxamine; PLP, pyridoxal 5’-phosphate; PNP, pyridoxine 5’-phosphate; PMP, pyridoxamine 5’-phosphate; PA, 4-pyridoxic
acid. All units nmol/L, except for PNP which is stated in ‘concentration units’. Values outside the reference range are shown in bold. 1Albersen et
al., 201517; 2Limit of quantification for PN/PMP (Albersen et al., 2012)18; 3Measurement taken 2 days after starting pyridoxine; 4Reference range
for local lab (26 – 69); 5Subject received tapered PLP withdrawal trial. CSF collected 48 hours after last dose. Duplicate measurements of same
sample given for Subject 5.
Table 5. CSF Monoamine Metabolite, Pterin and Folate Results of PROSC-Deficient Subjects
Subject 2 Subject 4 Subject 5** Subject 5** Subject 6
19 m 6 d 21 d 17 m 20 m
B6 supplementation Yes* No No No Yes
Homovanillic acid 755 (295 - 932) 310 (324 - 1098) 886 (484 -1446) 770 (364 - 870) 556 (154 - 867)
5-Hydroxyindoleacetic acid 223 (114 - 336) 376 (199 - 608) 538 (302 - 952) 387 (155 - 359) 158 (89 - 367)
3-Ortho-Methyldopa 46 (<300) 586 (<300) 508 (0 - 310) 84 (0 - 50) nm
L-Dopa 22 (< 25) nm 200 (0 - 15) <2 (0 -15) nm
5-Hydroxytryptophan 105 (< 10) nm 32 (0 - 20) 28 (0 -15) nm
5-MTHF 89 (64 -182) 120 (72 - 305) 97 (62 - 287) 113 (37 - 214) nm
Tetrahydrobiopterin 10 (15 - 40) 71 (27 - 105) 12 (25 - 121) 35 (20 - 61) nm
7,8-Dihydrobiopterin 12 (12 - 30) 17 (0.4 - 13.9) 8 (0 - 18) 4 (0 - 18) nm
Total Neopterin nm 124 (7 - 65) 17 (6 - 59) 6 (5 - 53) nm
Results expressed as nmol/l. d = day, m = month, 5-MTHF = 5-methyl-tetrahydrofolate *Treated prophylactically. Subjects 2, 4 and 5 display
some biochemical features of aromatic L-amino acid decarboxylase (AADC) deficiency; elevated concentrations of 3-ortho-methydopa, L-dopa
and 5-hydroxytryptophan, low homovanillic acid. Subject 5 also had raised urinary vanillactic acid on several occasions although this normalised
(additional details case history). **Plasma L-aromatic amino acid decarboxylase (AADC) activity markedly decreased at 1 m (12 pmol/ml/min;
reference range: 47 - 119), marginally decreased at 7 m (44 pmol/ml/min; reference range; 47-119) and normal at 17 m (50 pmol/ml/min; reference
range; 33-79); no mutations were found in AADC. Values highlighted in bold are outside of the reference range. Age related reference range
given in parentheses.
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Clinical Histories
Subject 1 (Fig. 2A. IV.1) was born prematurely at 32 weeks gestation with an Apgar
score of 5,10,10. He was small for gestational age with a birth weight (BW) of 1420 g, length
of 36 cm and a head circumference (HC) of 27.5 cm (25-50th centile). He had anemia at birth
which required blood transfusions and he also developed metabolic acidosis that required
buffering; blood lactate was elevated. Myoclonic seizures started immediately after birth.
EEGs showed only reduced background activity. Treatment with phenobarbital had no effect.
At 5 days, 50 mg pyridoxine hydrochloride was given i.v. and led to immediate cessation of
seizures, muscular hypotonia and apnea with respiratory acidosis requiring continuous
positive airway pressure (CPAP). He did not receive any further pyridoxine treatment
because of the pronounced reaction. At 1 week, he developed necrotizing enterocolitis that
was treated surgically with resection of the transverse and descending colon and formation
of a colostomy. The EEG deteriorated after the operation with a burst-suppression pattern
and frequent subclinical seizures. He also developed more pronounced clinical seizures -
tonic seizures, myoclonic jerks and epileptic grimacing, not controlled by phenobarbital or
vigabatrin. A brain CT at 2 months showed underdevelopment of the brain with broad gyri
and shallow sulci and a cyst adjacent to the left frontal horn. At 3 months the colostomy was
closed. After this the seizures increased and were not controlled by midazolam,
phenobarbital, lignocaine hydrochloride, valproate and betamethasone. He was therefore
intubated and sedated with sodium thiopental. He initially became seizure-free but the
seizures returned when the sedation was tapered. At 4½ months, he was again given i.v.
pyridoxine HCl 50mg; there was immediate freedom from seizures and the EEG recordings
normalized within 3 min. However, he had developed cardiac failure and was felt to have a
very poor prognosis; a decision was made to terminate the ventilator treatment and he died.
Subject 2 is the younger brother of Subject 1 (Figure 2A; IV.2); his mother was treated
with 100 mg pyridoxine HCl daily throughout pregnancy. She felt rhythmic jerks from the fetus
during the last 5 weeks of gestation. BW was 2940 g, length 48 cm and HC 33 cm (2nd – 9th
centile). The Apgar score was 8, 9, 10. Clinical examination at birth was normal except for
hypospadias. An EEG examination was normal. At 16 hours, the background activity became
abnormal and he developed a seizure originating from the right hemisphere with clinical
manifestations of irritability, myoclonic jerks, muscular hypertonia and apnoea. Treatment
with pyridoxine HCl 100 mg i.v. led to immediate seizure freedom and normalization of the
EEG. Treatment was continued with oral pyridoxine HCl 90 mg daily. His psychomotor
development has been delayed. He walked unsupported at 19 months and started to say
single words at 2 ½ years. Neuropsychological testing at 6 years of age showed moderate
learning disability. He is now 7 years of age and of normal weight and height but has a head
circumference at – 3 S.D. Clinical somatic and neurological examinations are normal except
for mild fine and gross motor dyspraxia and dysarthric speech. He has 3-4 seizures per year,
either generalized tonic-clonic seizures during sleep or myoclonic seizures during febrile
infections, and is currently treated with clobazam 10 mg and pyridoxine HCl 400 mg/day.
Recent EEG examinations have been normal. MRIs of the brain, performed at 3½ months
and 23 months of age, were essentially normal.
Subject 3 is a cousin of Subjects 1 and 2 (Fig. 2A; IV.6) and is the second child born
to healthy consanguineous Syrian parents. The pregnancy was normal. She was born at 36+6
weeks gestation. BW was 2720 g (25th- 50th centile), length 45 cm (9th-25th centile) and HC
32 cm (9th centile). The Apgar score was 8, 8, 9. In the first few hours of life she had episodic
dyspnoea and apnoea and at 6 hours she had a seizure with generalized stiffness, chewing
and cyanosis. EEG showed a burst suppression pattern with seizure activity. Intravenous
treatment with pyridoxine HCl 100 mg led to immediate freedom from seizures. The EEG
background activity became severely suppressed with very low amplitude that gradually
normalized and the seizure activity disappeared. She was then treated with oral pyridoxine
HCl 80 mg and folinic acid 7.5 mg, once daily (od). At 3 months of age she had several
generalized clonic seizures. Clobazam and carbamazepine were added and oral pyridoxine
HCl was switched to oral pyridoxal phosphate 70 mg qds. She has since then had monthly
seizures, mostly in relation to febrile infections. Her psychomotor development has been
delayed. At 3 years she had a developmental age around 6 months. She gave a social smile,
had monosyllabic babbling, grasped with her whole hands, moved objects with her hands to
her mouth, and was able to roll over, but not to sit unsupported. Clinical examination revealed
her HC was at -4 SD. Muscle tone and tendon reflexes were normal. MRI of the brain at 26
months showed wide ventricles and extracerebral spaces with severely reduced
periventricular white matter and a thin corpus callosum.
Subject 4 was the second child born to consanguineous British Asian parents; her
brother is well. During the pregnancy, oligohydramnios was noted at 28 weeks (but
subsequently resolved), and mother felt abnormal fetal movements. The birth at 36+3 weeks
gestation was complicated by meconium staining of the liquor but no other signs of fetal
distress. BW was 3.20 kg (<10th centile) and Apgar scores were 7, 8, 8. However, the infant
collapsed at 10 minutes and developed a mixed respiratory and metabolic acidosis with a
blood lactate of 21 mM. She required intubation and ventilation. She was jittery and
hypertonic, and developed a pyrexia. She had abdominal distension with dilated loops of
bowel on an abdominal X-ray. She was anemic and had a transfusion. Seizures, evident from
20 hours included jaw twitching, eye blinking and hiccups. Investigations revealed only a
slightly low plasma magnesium with normal calcium. Seizures were resistant to
phenobarbitone, phenytoin, a clonazepam infusion and levetiracetam; a bolus of midazolam
produced temporary relief. An EEG on day 2 showed a burst suppression pattern. Pyridoxine
(100 mg/d) was given i.v. from day 4 while the infant was still being ventilated. Seizures
ceased rapidly and clonazepam and midazolam could be weaned over the next 3 days;
levetiracetam was continued. Four days after starting pyridoxine treatment, she could be
extubated and pyridoxine treatment continued via a nasogastric tube. An MRI scan at 10
days showed global underdevelopment of the brain and also white matter edema with
asymmetrical hemorrhages in the deep white matter. The latter changes had resolved by 2
months. When urine analysis indicated normal urinary excretion of -aminoadipic
semialdehyde (AASA) and a diagnosis of pyridox(am)ine phosphate oxidase deficiency was
suspected, treatment was changed to pyridoxal 5’-phosphate (25 mg tds) by the
oral/nasogastric route. This treatment has been continued at 45 mg/kg/d ever since.
Treatment with levetiracetam was also continued and later attempts to discontinue this
anticonvulsant led to recurrence of seizures. Seizure control on PLP and levetiracetam was
as good as, or perhaps even better than, on pyridoxine and levetiracetam. Unfortunately the
infant has shown significant developmental delay; she was able to roll over and sit with
support at 13 months. Her HC, which had been on the 90th centile at 3 weeks, fell to between
the 25th and 50th centiles at 14 months. She is now 3 years 6 months old and has clear delay
in language and social communication skills (non-verbal) and still experiences infrequent
seizures which occur in clusters often with fever. An MRI scan at 2 years showed white matter
signal change and white matter volume loss (T2 weighted images).
Subject 5 was the second child born to non-consanguineous German parents; her
brother is well. Pregnancy ultrasounds suggested intrauterine growth retardation and
oligohydramnios. Severe oligohydramnios was present at 35 weeks and a cardiotocogram
(CTG) showed pathological fetal tachycardia so she was delivered by emergency caesarean
section. BW was 2.13 kg (10th centile). Birth HC was 30cm (9th centile UK-WHO). Apgar
scores were 8, 8 and 9. Mild dysmorphic features were noted - upslanting palpebral fissures,
mild telecanthus, a wide nose, prominent nasal bridge, broad face, and full cheeks. In the
first hours of life she was noted to be irritable, tachypnoeic at times, bradypnoeic with a mild
respiratory acidosis at others. She was treated with CPAP. She was tachycardic and pyrexial.
At 12 hours, she had a bout of hyperexcitability and myoclonic jerks were seen. She had a
metabolic acidosis with raised blood lactate (8-19 mM) and CSF lactate (9.8 mM). Seizures
continued and included tonic elevation of her arms, other spasms, lip smacking and facial
grimacing. An EEG showed a burst suppression pattern as well as multifocal spikes. At 2
days she was given pyridoxine 100 mg i.v. followed by 20 mg per day orally along with
phenobarbitone. She had some bradypnoea but seizures ceased for 7 days and the EEG
improved. After 7 days, pyridoxine was discontinued but seizures recurred after 2 days.
During the 2nd and 3rd weeks of life seizures were partially controlled by phenobarbitone
and levetirecetam. Oral pyridoxine (20mg daily) was reintroduced at 4 weeks and improved
seizure control. At 6 weeks PLP was introduced at a dose of 10 mg/kg tds. This led to
resolution of the multifocal spikes on the EEG. Treatment with PLP was continued throughout
the first 17 months at a dose of 40 mg/kg/d together with levetiracetam. The neonatal MRI
scan showed large ventricles, broad gyri and shallow sulci, reduced white matter bulk,
periventricular germinolytic cysts and a slim thoracic spinal cord. A repeat scan at 7 months
showed reduced brain volume and reduced white matter bulk but age-appropriate
myelination. Further MRI scans at 1 year 6 months, and at 3 years 11 months, showed
massive brain atrophy, due to underdevelopment of white matter. At 17 months a tapered
PLP withdrawal led to recurrence of seizures within 24 hours in the form of myoclonic jerks.
Subsequently treatment with PLP (10 mg/kg tds) and levetiracetam was continued with good
seizure control. Seizures sometimes occurred with febrile illness, taking the form of tonic
seizures and simple partial motor seizures. Assessment at 5 years 4 months showed severe
psychomotor delay (speech and understanding 12.5 months, expressive speech <11 months,
perception <11 months, gross and fine motor skills <11 months). Her HC had fallen from the
9th centile to -4.4SD, with no head growth since 3 years 6 months. Furthermore growth failure
had occurred with a height 3.4SD below the mean.
Subject 6 was the product of the second pregnancy of first cousin British Indian
parents. The first pregnancy unfortunately resulted in intrauterine death at 22 weeks with
evidence of infection and facial deformity. Subject 6 was born at 39 weeks gestation following
evidence of fetal distress (a suboptimal CTG and meconium-stained liquor). BW was 3.25kg
and birth HC 33cm (9th centile). Apgar scores were 9 at 1 minute and 9 at 5 minutes. He was
irritable and hypertonic and at 2 hours started to have seizures (probably tonic although there
was a clonic phase too). He developed respiratory distress at 16 hours. At 24 hours of age
he had his first major seizure, which mother describes as jerky movements of both arms and
legs lasting 5 minutes; he had abnormal tone with back arching. At 48 hours he had a further
seizure, for which he was given a trial of pyridoxine (200mg i.v.) and the seizures stopped
immediately. Effective control continued with reduction of seizures to 1 per week. At 4 days,
an EEG showed that there were variable periods of low amplitude burst suppression lasting
from 10 – 12 seconds, however, all subsequent EEGs have shown no evidence of interictal
epileptiform activity. Treatment was changed from oral pyridoxine to oral PLP (40 mg/kg/d ÷
4) at 5 months. This resulted in improved seizure control but even with additional
anticonvulsant therapy (phenobarbitone and leviteracetam) he had seizures once a month.
A trial of PLP withdrawal at 11 months led to recurrence of seizures within a few hours and
PLP was restarted at 40 mg/kg/d. Subsequent seizures have been generalized tonic-clonic
seizures: typically a 5-10 minute seizure, which mother describes as both arms and legs
having jerking movements and being unresponsive for 5 minutes prior to arching his back
and his eyes rolling for a further five minutes. Seizures are often associated with fever.
Subject 7, an Italian boy, is now 16 years old. His parents are not consanguineous.
The pregnancy was uneventful and he was born at 39 weeks gestation with normal BW (3.05
kg), HC (34cm; 25th-50th centile) and Apgar scores (9, 9, 10). There were no problems in the
early neonatal period but he developed generalised tonic clonic seizures at 1 month. An EEG
showed good background activity but multifocal abnormalities. He was treated sequentially
with carbamazepine plus clobazam, clobazam plus nitrazepam (NZP), and NZP plus
felbamate (FBM). He showed partial seizure control with these anticonvulsants. At the age of
23 months, after many recurrent partial and generalized seizures over a few days, he was
given a trial of pyridoxine at a dose of 300 mg per day which resulted in complete cessation
of seizures. Since the age of 8 years he has only received pyridoxine with all other treatments
having been stopped. He is currently receiving a dose of 250 mg/d. He has had very good
seizure control with only occasional breakthrough seizures with febrile illnesses. IQ
measurements indicated a score of 76 at 3 years (Griffiths), 65 at 9 years (Raven’s
progressive matrices) and 60 with good adaptive skills at 17 years (Raven’s progressive
matrices). He was able to attend normal school and now leads a normal life. His brain MRI is
normal.
Figure S1. Sequence Chromatograms. For each affected subject, the top chromatogram shows
the wild-type (WT) PROSC sequence and the chromatogram below the PROSC mutation (Mut)
identified in the affected individual. Parental studies for Subjects 1-3, 4, and 6 demonstrated that
both parents are heterozygous carriers of the identified mutation. Parental studies for Subject 5
revealed that c.207+1G>A and c.320-2A>G were carried on the maternal and paternal allele,
respectively. In the case of Subject 7, c.260C>T and c.722G>A were carried on the maternal and
paternal allele, respectively. S = subject.
c.524T>C; p.[Leu175Pro]
S2 S4
c.233C>G; p.[Ser78Ter]
WT
Mut
S5
c.207+1G>A
S5
c.320-2A>G
c.211C>T; p.[Gln71Ter]
S6
WT
Mut
c.260C>T; p.[Pro87Leu]
S7
c.722G>A; p.[Arg241Gln]
S7
WT
Mut
Figure S2. Sequence alignment of PROSC homologues. Residues identical to
human PROSC are marked with an asterisk (*). Conservation between amino acids of
strongly and weakly similar properties is indicated by a colon (:) and a period (.),
respectively. Amino acids affected in humans by missense mutations are highlighted by
a red box. Leu175 and Arg241 are conserved across PROSC and other members of the
COG03.25 family (F09ES.8, YBL036C and YggS). Pro87 is only conserved across
PROSC. PROSC is highly conserved among divergent species. The overall sequence
identity for the entire amino acid sequence between; human and mouse is 86.5 %,
human and E. coli is 35.9 %, human and Saccharomyces is 40.3 %. PROSC (higher
organisms), F09ES.8 (worm), YBL036C (arabidopsis and yeast) and YggS (bacteria)
sequences are highlighted in blue, orange, yellow and pink, respectively.
F09ES.8
HAVEVGSTNVRIGSTIFGERD
HAIEVGSTNVRIGSIIFGERD
HAIEVGSTNVRIGSTIFGERD
HAIEVGSTNVRIGSTIFGERD
HAIEVGSTNVRIGSTIFGERD
HAIEVGSTNVRIGSTIFGERD
HAIEVGSTNVRIGSTIFGERD
HAIEVGSTNIRVGSTIFGTRE
HAIEVGSTNVRIGSTIFGERD
HAIEVGSTNVRIGSTIFGERS
HAIEVGSTNVRIGSTIFGERV
NAIEAGSTIVRVGSAIFGFRA
HAIEVGSTNVRVGSTIFGNRD
QAIHQGATSVRVGSKLFGARE
LAIEMGSTNVRVGSTIFGPRE
EAIRQGTAEVRIGTDIFGARP
AAIAAGSTMVRIGTAIFGARD
IAIKCGSNMVRLGSILFKNLK
AAIGEGATWVRIGTALFGARD
EAIQFGSTFVRIGTSFFK---
IAVEEGATFVRIGTKLVGEEE
*: : :*:* :.
Human NPKILSL-CPEIKWHFIGHL
Monkey NPKILSL-CPEIKWHFIGHL
Elephant NPKILSS-CPEIKWHFIGHL
Cow NPQILSS-CPEIKWHFIGHL
Bat NPKILSS-CPEIKWHFIGHL
Mouse NPKILSS-CPEIKWHFIGHL
Penguin DSRILSS-CPEIKWHFIGHL
Zebra Fish NPQILSS-CPEIKWHFIGHL
Zebra Finch DSRILSS-CPDIKWHFIGHL
Python DSRILSS-CPEIKWHFIGHL
Western Clawed Frog DPNLLAS-CPDIKWHFIGHL
Melon Fly HPDILQH-CPEIKWHFIGHL
Pike NPQVLES-CPEIEWHFIGHL
Worm --VLASK-CLDIRWHFIGQV
Arabidopsis ------L-PEDIEWHFVGHL
Saccharomyces ------L-PDDIKWHFIGGL
E.coli --HFQELGVTGLEWHFIGPL
Campylobacter --ILDKK-DLNIKWHFIGTL
Pseudomonas --E---LADLPLNWHFIGPI
Streptococcus ------LKNRDVTWHLIGTL
Staphylococcus ------LPS-DAVIHFIGSL
*::* :
PROSC
YBL036C
Pro87 Leu175
AKCPNLEFVGLMTIGSFGHD
AKCPSLEFVGLMTIGSFGHD
AKCPSLEFVGLMTIGSFGHD
AKCPSLEFVGLMTIGSFGHD
TKCPSLEFVGLMTIGSFGHD
ASCPSLEFVGLMTIGSFGHD
NKCPSLEFVGLMTIGSIGHD
SQCPALDLAGLMTIGRYGYD
NKCPSLEFVGLMTIGSIGHD
QKCPNLEFVGLMTIGSFGHD
EKCSSLEFVGLMTIGSFGYD
DNLKNLQLEGVMTIGAFGFD
NKCSALHFSGLMTIGRYGYD
KECQNLKFDGFMTIGSFDNS
HHCPNLVFSGLMTIGMPDYT
EECKYIKLNGLMTIGSWNVS
AELPRLRLRGLMAIPAPESE
EECPNLNLCGVMSIGSHSEE
KQLPNLRLRGLMAIPEPTAE
ARLDKIEYVGLMTMAPFEAS
KKYDKIEIVGLMTMAPLTDD
: *.* :
YggS
Arg241
Figure S3. Leu175 is Part of the microRNA Binding Site of hsa-miR-202-5p. Western blot analysis of mutant p.Leu175Pro PROSC (Subject 4)
revealed that no protein was detectable for this variant. Prediction analysis of PROSC using the MicroT-CDS web based programme
(http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=microT_CDS/index) (Paraskevopoulou et al., 2013) revealed that p.Leu175 (c.524T)
is involved in an 8mer binding site at position 524-552 in the coding sequence of PROSC to which the microRNA (miRNA) hsa-miR-202-5p binds.
miRNA sites located in the coding sequence (CDS) have been shown to be effective in inducing translation inhibition. Generally imperfect
complementarity between miRNAs and their target sites occurs with extensive mismatched bulges especially in the central region (Standart & Jackson,
2007) as depicted. Leu175Pro may enhance the affinity of the PROSC transcript for the hsa-miR-202-5p (Amato et al., 2013). MicroRNA (miRNA)
sequence is in pink, PROSC mRNA target sites in blue. Position of miRNA binding site on chromosome 8:37632927-376632955.
c.525
Wild-type (30.3kDa) MWRAGSMSAELGVGCALRAVNERVQQAVARRPRDLPAIQPRLVAVSKTKPADMVIEAYGH
P5.1 (8.1kDa) MWRAGSMSAELGVGCALRAVNERVQQAVARRPRDLPAIQPRLVAVSKTKPADMVIEAYGH
P5.2 (29.2kDa) MWRAGSMSAELGVGCALRAVNERVQQAVARRPRDLPAIQPRLVAVSKTKPADMVIEAYGH
P5.3 (26.4kDa) MWRAGSMSAELGVGCALRAVNERVQQAVARRPR---------------------------
Wild-type GQRTFGENYVQELLEKASNPKILSLCPEIKWHFIGHLQKQNVNKLMAVPNLFMLETVDSV
P5.1 GQRTFGENYIRALS*---------------------------------------------
P5.2 GQRTFGENYVQELLEKASNPKILSLCPEIKWHFIGHLQKQNVNKLM----------VDSV
P5.3 ---------VQELLEKASNPKILSLCPEIKWHFIGHLQKQNVNKLMAVPNLFMLETVDSV
Wild-type KLADKVNSSWQRKGSPERLKVMVQINTSGEESKHGLPPSETIAIVEHINAKCPNLEFVGL
P5.1 ------------------------------------------------------------
P5.2 KLADKVNSSWQRKGSPERLKVMVQINTSGEESKHGLPPSETIAIVEHINAKCPNLEFVGL
P5.3 KLADKVNSSWQRKGSPERLKVMVQINTSGEESKHGLPPSETIAIVEHINAKCPNLEFVGL
Wild-type MTIGSFGHDLSQGPNPDFQLLLSLREELCKKLNIPADQVELSMGMSADFQHAVEVGSTNV
P5.1 ------------------------------------------------------------
P5.2 MTIGSFGHDLSQGPNPDFQLLLSLREELCKKLNIPADQVELSMGMSADFQHAVEVGSTNV
P5.3 MTIGSFGHDLSQGPNPDFQLLLSLREELCKKLNIPADQVELSMGMSADFQHAVEVGSTNV
Wild-type RIGSTIFGERDYSKKPTPDKCAADVKAPLEVAQEH
P5.1 -----------------------------------
P5.2 RIGSTIFGERDYSKKPTPDKCAADVKAPLEVAQEH
P5.3 RIGSTIFGERDYSKKPTPDKCAADVKAPLEVAQEH
Figure S4. Predicted PROSC Amino Acid Sequence for cDNA Splice Variants Detected in Subject 5.
cDNA was generated from RNA extracted from fibroblasts of control individuals and Subject 5. Figure 3 in
the main text shows that only one product (846bp) was evident for the control samples whilst three bands
(923bp, 827bp and 816bp cDNA products) were evident for Subject 5. The products were cloned into TOPO-
2.1 and sequenced. The amino acid sequences shown were predicted from the nucleotide sequences
obtained. Protein P5.1 (corresponding to the 923bp cDNA band) and P5.3 (816bp band) were shown to
originate from c.207+1G>A and P5.2 (827bp band) from c.320-2A>G. Alternating exons highlighted in black
and blue. Amino acid highlighted in red indicates residue overlap splice site. Amino acids depicted in green
highlight the consequence of c.207+1G>A. The predicted molecular masses of wild type and Subject 5
PROSC products are as indicated in parentheses. Immunogen sequence of antibody (used in Fig 3b in the
paper) highlighted in wild-type sequence (bold/underlined). The antibody would not be expected to detect
P5.1 (8.1 kDa) as the antibody site has been deleted. It also does not detect P5.2 (29.2 kDa) probably
because the first nine amino acids of the recognition sequence have been deleted (Fig 3b). The 26.4 kDa
product is however visible (Fig 3b) as expected. An alternative antibody was used that targeted the N’
terminus of the protein however this was found to be very nonspecific.
Figure S5. Quantification of Total Pyridoxal (PL) in Fibroblasts from Controls and Subjects 2, 4 and
5 and from the Mother of Subject 2 (Heterozygous for Ser78Ter). PL was analysed by LC-MS/MS,
quantified relative to a known amount of internal standard [D3-PL] and expressed as a ratio to cell protein.
Data are presented as means ± 1 s.d.. Statistical analysis was performed using Student’s two tailed t test;
Subject 2 is statistically different to controls (p=0.0234). No statistical difference between Controls and
Subjects 4 and 5 and Heterozygote. QC = quality control sample
*
Figure S6. Amount of PLP Present in Low and High Molecular Weight Fractions of
Control and PROSC-Deficient Fibroblasts.
(A) <3 kDa fraction and (B) > 3 kDa fraction. Controls; duplicate measurements of n= 3.
Samples from subjects with PROSC deficiency; duplicate measurements of n = 2. Error bars
show SEM. PROSC-deficient cells significantly different to controls; p < 0.001.
A
B
Figure S7. PROSC Protects PLP and Regulates Intracellular PLP Concentrations
Proposed disease mechanism. Pyridoxal (PL) enters the cell and is (a) phosphorylated by
pyridoxal kinase and PLP is transferred to the PLP-binding site within the β-barrel of PROSC 
thereby maintaining free PLP at low concentrations preventing inappropriate reactions with other
reactive molecules and protecting it from dephosphorylation by intracellular phosphatases. (b)
PROSC transfers PLP to B6-dependent apo-enzymes resulting in formation of a functional holo-
enzyme. During the enzyme reaction catalysed by the B6-dependent holoenzyme PMP may be
formed and released (c) PNPO oxidises PMP to PLP prior to transferring it to PROSC. (d) When
PROSC is dysfunctional (indicated by a red X) it cannot protect PLP resulting in (e) PLP being
de-phosphorylated by endogenous cellular phosphatases and the amount of PL increasing or
(f) PLP reacting with small molecules and proteins other than PLP apo-enzymes. Whilst the
amount of total bound PLP in the cell is high when supplemented with supraphysiological
concentrations of B6, under normal conditions the amount of PLP available to B6 apo-enzymes
is insufficient. In PROSC-deficient individuals, this presents as B6-dependent epilepsy.
Primer Sequence (5’ → 3’) Amplicon
size (bp)
PROSCEx1F AGCTAAGCGCGAGAAGGCGCTCCATTTCCAGGTTCG 379
PROSCEx1R GCTTTACCGCTCAACCGTTCGTGACGACCCATTCCC
PROSCEx2F AGCTAAGCGCGAGAAGGCCAAGTTGAGATCAATGCCTGTC 410
PROSCEx3R GCTTTACCGCTCAACCGTTACAACTCAACCACCAGGATG
PROSCEx4F AGCTAAGCGCGAGAAGGCCAGAGAGTGGATGTGAAAGGTG 364
PROSCEx4R GCTTTACCGCTCAACCGTTTGGTGAATTCATTCTGTTCTTG
PROSCEx5F AGCTAAGCGCGAGAAGGCTGTTTTTCTTTTCCTGGCATA 370
PROSCEx5R GCTTTACCGCTCAACCGTTGGCCTGTGATCCTGTGATTT
PROSCEx6F AGCTAAGCGCGAGAAGGCGTTCTCTTGTTGGGGGTCAC 361
PROSCEx6R GCTTTACCGCTCAACCGTTAGGCAGTGTCTGGGATGACT
PROSCEx7F AGCTAAGCGCGAGAAGGCAACCGTTGTCAGAGAAGTTCAG 285
PROSCEx7R GCTTTACCGCTCAACCGTTTTCCAAGGCTTCTACAGCAAAG
PROSCEx8F AGCTAAGCGCGAGAAGGCCCCGTCCATAGAAGGCTC 664
PROSCEx8R GCTTTACCGCTCAACCGTTGACGACGTAGTAGGAGTTTGTAGG
ForwardSeq AGCTAAGCGCGAGAAGGC na
ReverseSeq GCTTTACCGCTCAACCGTT na
Table S1. Tailed Primer Sequences and PCR Conditions Used for the Amplification of Human
PROSC. ID of transcript amplified ENST00000328195. Tailed primers were used to facilitate
downstream sequencing. ‘Tail’ sequence is highlighted in red and was incorporated into the PCR
product during amplification. PCR was performed using Taq DNA polymerase (Life Technologies) and
1.5 mM MgCl2. Exons 2 and 3 were amplified as a single amplicon. Cycling conditions: 95°C for 5
minutes; 35 cycles of 95°C for 30 seconds, annealing temperature 58°C for 30 seconds, 72°C for 30
seconds; final cycle 72°C for 10 minutes. PCR products were sequenced using primers based on the
‘tails’ that had been incorporated (called Forward Seq and ReverseSeq). na = not applicable
Primer Sequence (5’ → 3’) Amplicon size
(bp)
PROSCcDNAF GGGGATGTGGAGAGCTGG 379
PROSCcDNAR CAGTATTCCCTGGCTCAGTG
Table S2. Primer Sequences and Conditions Used for Amplification of Full-length Human
PROSC cDNA. Cycling conditions were 96°C for 2 minutes, followed by 35 cycles of 20 seconds at
95°C, 10 seconds at 50°C, 3 minutes at 60°C.
Primer Sequence (5’ → 3’)
PROSCcDNA1F GCTAGTGGCGGTCAGCAAAACC
PROSCcDNA2F GGTTAAAGGTTATGGTCCAGAT
PROSCcDNA3F GGACAAGTGCGCAGCAGACGTGAA
PROSCcDNA4F GGGCTGGATGGCTGGGAGATCC
PROSCcDNA5F AGCATGAAGAGATTGGGGACAGCC
PROSCcDNA6F CATGCCCATGCTCAGCTCAACC
PROSCcDNA7F CCATTGCCTGAAGCAAGCTTCC
Table S3. Primer Sequences and Conditions Used for Sequencing of Full-length Plasmidic
Human PROSC cDNA. Sequencing reaction conditions were 96°C for 2 min, followed by 35 cycles
of 20 sec at 96°C, 10 sec at 50°C, 3 min at 60°C.
Time
(min)
Mobile Phase A
(3.7% Acetic Acid
& 0.01%HFBA)
Mobile Phase
B
(100% MeOH)
Flow Rate
(ml/min)
Curve
0.00 97.5 2.5 0.4 0
0.40 97.5 2.5 0.4 0
3.75 50.0 50.0 0.4 6
3.76 0.1 99.9 0.4 11
4.26 97.5 2.5 0.4 1
5.00 97.5 2.5 0.4 1
Table S4. Mobile Phase Composition and HPLC Gradient Profile for the Separation of B6
Vitamers on a HSS T3 Column
Analyte Retention
time (min)
Precursor ion
(m/z)
Product ion
(m/z)
Cone Voltage
(V)
Collision Energy
(V)
PMP 0.87 249.04 134.05 27 22
PNP 1.00 250.04 134.04 27 16
PLP 1.00 248.00 150.01 27 16
D2-PLP 1.00 250.00 152.01 27 16
PA 1.09 184.06 147.99 18 18
D2-PA 1.09 186.06 149.99 18 18
PL 1.12 168.10 150.50 21 12
D3-PL 1.12 171.10 153.05 21 12
PM 1.12 169.12 134.04 22 20
D3-PM 1.12 172.12 137.04 22 20
PN 1.36 170.09 134.04 27 19
D2-PN 1.36 172.09 136.04 27 19
Table S5. The Mass Spectral Specifications for Detection of B6 Vitamers in Plasma, CSF and
Fibroblasts and their Deuterated Internal Standards. All are detected in positive ion mode.
Primer Sequence (5’ → 3’)
PROSCSer78XF
PROSCSer78XR
CAGGAACTGCTAGAAAAAGCATGAAATCCCAAAATTCTGTC
GACAGAATTTTGGGATTTCATGCTTTTTCTAGCAGTTCCTG
ProsC_L175P_FW
ProsC_L175P_RV
CCAAGTGTCCTAACCCGGAGTTTGTGGGGCTG
CGTTTATGTGCTCCACGATGGCTATGGTCTCT
ProsC_R241Q_FW
ProsC_R241Q_RV
GATCTACAAATGTCCAAATAGGAAGCACGAT
CTACTTCAACCGCATGCTGGAAA
ProsC_P87L_FW
ProsC_P87L_RV
ATTCTGTCTTTGTGTCTTGAGATCAAATGGCAC
TTTGGGATTTGATGCTTTTTCTAGCAGTTCC
Table S6. Primers used for Site-directed Mutagenesis to Generate PROSC Missense and
Nonsense Mutations.
gene Genomic position on
chrosome 8
ref/ alt allele dbSNP number Predicted effect on
protein
NKX3-1
NKX2-6
STC1
ADAM28 24211331 G/A rs7814768 missense
ADAMDEC1 24261526 A/G rs3765124 missense
ADAM7
NEFM
NEFL
DOCK5 25234858 A/G rs2659585 missense
GNRH1 25280706 G/G rs35542850 missense
KCTD9
CDCA2 25364331 G/A rs4872318 missense
EBF2
PPP2R2A
BNIP3L
PNMA2
DPYSL2
ADRA1A
STMN4
TRIM35
PTK2B 27308585 A/C rs751019 missense
CHRNA2
EPHX2
CLU
CCDC25
SCARA3
ESCO2
SCARA5
PBK
NUGGC 27918057 T/C rs7817227 missense
NUGGC 27925185 G/A rs74462442 missense
NUGGC 27927849 C/G rs6998705 missense
ELP3
PNOC
FBXO16
FZD3
ZNF395
EXTL3
INTS9
HMBOX1
KIFI3B
DUSP4
SARAF
LEPROTL1
MBOAT4
DCTN6 30034655 A/G Not reported previously missense
RBPMS
GTF2E2
GSR
SMIM18
UBXN8 30608976 C/T rs2911690 missense
PPP2CB
TEX15
PURG
WRN
NRG1 32453358 G/A rs3924999 missense
NRG1 32613983 T/C rs10503929 missense
FUT10
MAK16 33356074 A/G rs6468171 missense
TTI2 33369944 T/C rs2304748 missense
DUSP26
RNF122
UNC5D
KCNU1 36767024 T/C rs28608091 missense
ZNF703
ERLIN2
ADGRA2
PROSC 37623254 C/G Not reported previously Stop-gain
RAB11FIP1 37728017 A/G rs7817179 missense
GOT1L1
BRF2
ADRB3
EIF4EBP1
STAR
LSM1
ASH2L
BAG4
DDHD2
PLPP5
WHSC1L1
Table S7. Protein-coding Genes in the Homozygous Region at Chromosome 8p21.2-p11.23 (bp
23,451,893-38,236,890 GRCh37/hg19) Identified by Homozygosity Mapping and Single
Nucleotide Variants (SNVs) identified by Whole Exome Sequencing Shared Between Subjects
2 and 3. All SNVs identified in the region described were homozygous. Only non-synonymous coding
variants are described.
CSF amino acid concentration (μM) Plasma amino acid concentration (μM) 
Amino acid Substrate of
Enzyme
PLP-
dependent
reaction
Subject 4
(Age 6 d)
Subject 5
(Age 21 d)
Subject 5
(Age 17 m)
Subject 4
(Age 1 d)
Subject 5
(Age 21 d)
Subject 5
(Age 5 m)
B6* No B6 No B6 No B6 No B6 No B6
Alanine Alanine
aminotransferase
Yes1
Not available 49.3(28.5-38.0)
48.6
(23.0-39.5)
386
(112 – 686)
395
(131-460)
524
(100-439)
Valine2 Branched chain
amino acid
transaminase
Yes
Not available 32.3(18.2-25.0)
19.6
(14.8-22.5)
110
(96 – 566)
185
(80-120)
139
(60-294)
Isoleucine2 Branched chain
amino acid
transaminase
Yes
Not available 19.8(5.1-11.2)
8.9
(4.6-8.6)
20
(26-159)
55
(26-80)
40
(28-95)
Leucine2 Branched chain
amino acid
transaminase
Yes
Not available
26.7
(14.1-22.9) 8.2(11.0-18.7)
59
(50 – 264)
126
(46-160)
56
(45-160)
Glycine Glycine cleavage
enzyme
Yes
19
(2-15)
11.0
(5.9-8.5)
48.6
(23.0-39.5)
590
(81-303)
284
(224-514)
264
(60-380)
Phenylalanine2 Phenylalanine
hydroxlase
No3
Not available 14.9(8.3-15.9)
15.0
(7.0-13.2)
60
(34 – 110)
65
(38-120)
56
(23-75)
Proline Proline Oxidase No1 Not available 4.8(0-0.1)
0
(0-0.1)
523
(45-452)
249
(107-330)
154
(50-298)
Table S8. Abnormal Plasma and CSF Amino Acid Results of Samples from Subjects with PROSC Mutations and PLP Requirements of
Enzymes Involved in their Metabolism 1Raised alanine and proline could also be a consequence of mitochondrial dysfunction. Blood lactate was elevated
in the neonatal period in 3/5 subjects and MRS of subject 5 at 7 months showed that there was persistence of lactate accumulation in the brain. 2Essential
amino acids; increases seen may reflect dietary intake and not necessarily the lack of availability of PLP 3Product of reaction is tyrosine which is involved in a
PLP-dependent reaction *Sample taken after subject had been supplemented with B6 for 2 days; d = days; m = months. Values highlighted in bold are above
and below the age-related reference range. Age related reference range given in parentheses.
 Tyrosine concentration (μM) 
Age CSF Plasma
2.5 m 49 (1 - 22) nm
4 m 29 (1 - 22) nm
7 m 27 (1 - 22) nm
17 m 11 (4 - 12) 46 (50 -125)
5 y nm 166 (50 - 125)
Table S9. Tyrosine Concentrations in CSF and Plasma for Subject 2 whilst Receiving B6 Supplementation
m = months; y = years; nm = not measured. Elevated tyrosine levels not evident in samples analysed prior to supplementation with vitamin B6.
Values highlighted in bold above the age-related reference range. Age related reference range given in parentheses.
Age Homocarnosine concentration (μM) 
21 d 0 (3.9 - 7.7)
17 m 0 (4.3 - 10.4)
Table S10. Homocarnosine Concentrations in CSF for Subject 5 whilst not Receiving B6 Supplementation
d = days; m = months. Abnormal homocarnosine levels highlighted in bold. Age related reference range given in parentheses. Homocarnosine
was not measured in other PROSC-deficient subjects.
Age B6 [dose] PLP PL PA PN PNP PMP PM
Control range* None 15 - 75 nm nm nm nm nm nm
Subject 2* 1 d** PN [50 mg BD] 174 nm nm nm nm nm nm
1 w PN [50 mg BD] > 300 nm nm nm nm nm nm
11 m PN [150 mg BD] 4371 nm nm nm nm nm nm
Control range* None 7 - 233 8 - 129 4 - 171 nd nm nd nd
Subject 5* 2 y 7 m PLP [36 mg/kg/day] 1030 2280 5020 nd nm nd nd
Control range*** 4.3 y – 16 y None 46 - 321 5 - 18 16 - 139 nd - 0.6 nd nd - 9 nd
Subject 2 6 y PN [200 mg BD] 2626 2559 5522 2 nd nd nd
Subject 3 3 y PLP [70 mg QDS] 2769 796 2043 0.5 nd nd nd
Subject 4 6 m PLP [45 mg/kg/day] 2166 1695 700 nd nd nd nd
PNPO**** 2 y PLP [30 mg/kg/d] 580 427 793 575 43 18 193
PNPO**** 10 y PLP [30 mg/kg/d] 633 5798 7926 599 77 101 2731
PDE**** 10 y PN [100 mg BD] 24 6351 5904 60 nd 15 108
PDE**** 12 y PN [100 mg BD] 11 6476 5069 7 nd 24 144
PDE**** 8 y PN [100 mg BD] 588 198 239 0.4 nd nd nd
PDE**** 8 y PN [100 mg BD] 603 203 321 0.4 nd nd nd
Table S11. Plasma B6 Vitamer Profiles for Subjects with PROSC Deficiency, PNPO Deficiency and Pyridoxine Dependent Epilepsy due to Mutations
in ALDH7A1 (PDE) nd; not detected, nm; not measured. PL, pyridoxal; PN, pyridoxine; PM, pyridoxamine; PLP, pyridoxal 5’-phosphate; PNP, pyridoxine 5’-phosphate; PMP,
pyridoxamine 5’-phosphate; PA, 4-pyridoxic acid. All units nmol/L, except for PNP which is stated in ‘concentration units’. Values outside the reference range are shown in bold.
BD = twice a day; QDS = four times a day. *Samples measured in local laboratory; **received PN prophylactically; ***Samples measured at UCL using method and reference
range as described in Footitt et al., 2013; ****Data from Footitt et al., 2013. Comparisons between PROSC deficient subjects and individuals with PNPO and PDE deficiencies
receiving comparable supraphysiological doses of B6 was only made for individuals measured in the laboratories at UCL and the National Hospital, London; these labs partook
in a quality control scheme.
Subject Alkaline Phosphatase activity (U/L) WES analysis
2 394 (70 - 282); 171 (129 - 506) yes; no variants detected
3 - yes; no variants detected
4 233 (137 - 264) not performed
5 156 (35 - 398); 358 (122 - 334); 351 (122 - 334);
194 (105 - 310); 171 (105 - 310)
not performed
6 207 (35 - 398); 308 (122 - 334); 334 (122 - 334) not performed
7 166 (150 - 300); 147 (150 - 300) not performed
Table S12. No Evidence of Hypophosphatasia Due to Mutations in Tissue Non-Specific Alkaline Phosphatase in Subjects with PROSC
Deficiency Relevant age-related range for the individual subjects in parentheses.
1mg/ml pyridoxine 0.1mg/ml pyridoxine
1st zone of inhibition (cm) 2nd zone of inhibition (cm) 1st zone of inhibition (cm) 2nd zone of inhibition (cm)
ΔyggS 2.25 ± 0.10
(n=3)
2.60 ± 0.10
(n=3)
1.88 ± 0.20
(n=3)
0.78 ± 1.36
(n=3)
Wild-type
PROSC
No zone
(n=3)
No zone
(n=3)
No zone
(n=3)
No zone
(n=3)
Ser78Ter 2.29 ± 0.11
(n=4)
2.58 ± 0.10
(n=4)
1.89 ± 0.16
(n=4)
2.23 ± 0.19
(n=3)
Leu175Pro 2.22 ± 0.22
(n=6)
2.45 ± 0.28
(n=5)
1.92 ± 0.12
(n=5)
2.30 ± 0.18
(n=4)
Pro87Leu No zone
(n=3)
No zone
(n=3)
No zone
(n=3)
No zone
(n=3)
Arg241Gln# 4.45 ± 0.43
(n=6)
see legend 3.53 ± 0.44
(n=6)
see legend
Table S13. Quantification of Zone of Inhibition (Inner Radius) and Zone of Inhibition (Outer Radius) for E.coli Complementation Studies
The sensitivity to pyridoxine is defined as the distance from the disc, which has been impregnated with 20 L of pyridoxine, on the media where
the ΔyggS strain does not grow. 1mg/ml pyridoxine; disc a in Figure 6; 0.1mg/ml pyridoxine; disc b in Figure 6. n = number of replicates in
parentheses; # only 1 circle of inhibition observed after complementation of ΔyggS with Arg241Gln. No circle of inhibition was evident for Pro87Leu
and wild-type PROSC as they were able to complement the ΔyggS background and prevent the pyridoxine sensitivity at both concentrations of
pyridoxine used.
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